Olokizumab Tops Placebo for RA Patients Receiving Methotrexate
Olokizumab superior to placebo and noninferior to adalimumab in producing ACR20 response at 12 weeks
Rheumatoid Arthritis
FDA Approves Citrate-Free, High Concentration of Biosimilar Hadlima
The approval was based on data from a phase 1 study that compared the pharmacokinetics, safety, tolerability, and immunogenicity of Hadlima 100mg/mL to 50mg/mL.
Increased Cardiovascular Risks With Hydroxychloroquine vs Methotrexate in RA
Researchers evaluated the cardiovascular safety of hydroxychloroquine vs methotrexate among patients with rheumatoid arthritis.
Azathioprine Discontinuation Up for Patients With CC Genotype
Patients with rs2814778-CC also have lower last leukocyte count and lower dosing; findings persist after adjustment for race
Biosimilar Riabni Approved for Rheumatoid Arthritis
The approval is supported by data from a phase 3 study that compared the efficacy, safety, pharmacokinetics and immunogenicity of Riabni to rituximab reference products.
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
DMARD Prescribing Low for Older Adults With Rheumatoid Arthritis
Any DMARD use recorded at 56 percent of rheumatologist visits and 30 percent of primary care provider visits
Methotrexate-Related AEs Profiled in Early Rheumatoid Arthritis
Adverse events common during first year of methotrexate therapy for early rheumatoid arthritis, but most not serious
CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
Purified Cortrophin Gel Now Available for Certain Chronic Autoimmune Disorders
The product is available through a network of specialty pharmacies and distributors.
